Exon 19 deletion and exon 21 L858R point mutation make up the majority (> 90%) of all EGFR mutation-positive NSCLC [16, 17], which frequently leads to lung tumorigenesis and sensitivity to EGFR-targeted therapies [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.